Pet Financial News
Telix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI
MELBOURNE, Australia, June 22, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reveals discussions from the Company's investigational prostate (prostate...
Pet Financial News
Detailed Results from Telix’s ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU
Trial fulfilled main and secondary endpoints and verified beneficial safety and tolerability profile, showing TLX250-CDx has the prospective to end up being a brand-new...
Pet Financial News
Detailed Results from Telix’s ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU
Trial satisfied main and secondary endpoints and verified beneficial safety and tolerability profile, showing TLX250-CDx has the possible to end up being a brand-new...
- Advertisement -
Other News
Ukraine war news– live: Putin launches frigate equipped with hypersonic Zircon cruise weapons
Ratings of Russian soldiers apparently killed in Ukrainian attack Free of charge actual time breaking news signals sent out directly to your...
Pet Financial News
Heidelberg Pharma’s Partner Telix Reports Favorable Information on the Critical ZIRCON Research Study
EQS-News: Heidelberg Pharma AG/ Keyword( s): Alliance Heidelberg Pharma's Partner Telix Reports Favorable Information on the Critical ZIRCON Research Study 07.11.2022/...
Pet Financial News
Telix Reveals Favorable Topline Outcomes of ZIRCON Stage III Kidney Cancer Imaging Research Study
Summary of Research Study Results ZIRCON Stage III research study of Telix's investigational imaging representative TLX250-CDx in clear cell kidney cell cancer...
- Advertisement -
Pet Financial News
Telix Reveals Favorable Topline Outcomes of ZIRCON Stage III Kidney Cancer Imaging Research Study
Summary of Research Study Results ZIRCON Stage III research study of Telix's investigational imaging representative TLX250-CDx in clear cell kidney cell cancer...
-Advertisement-
Must read
-Advertisement-